Curcumin and Retinal Amyloid-beta Pilot Study

Curcumin-Retinal Pilot Study

To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.

2023-08-21

2025-03-31

2025-03-31

Recruiting

Early phase I

60

Inclusion: * Both male and female, age 40 - 89 years. * Diagnosed with Aβ deposits in retina (peripheral superior quadrants)--to be confirmed after consent obtained. If there is documentation the potential participant has been diagnosed with Aβ deposits in retina within 6 months before the consent session, we will use this diagnosis/documentation for eligibility criteria. Otherwise, the ophthalmic exam will be repeated after consent is obtained for the study. * No pre-existing liver or kidney diseases by self-report. Exclusion: * Patients with ocular diseases (macular degeneration, severe diabetes retinopathy) * Had used systemic antibiotics within 1 month prior to the start of the study intervention * Had taken any turmeric or curcumin products within 2 weeks prior to the start of the study intervention * Had a known allergy to black pepper * Women that are pregnant or breastfeeding

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'This is a 2-week double blinded, placebo-controlled, and randomized intervention trial with allocation 1:1 for two treatment arms (low curcumin group and high curcumin group).', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}

2023-08-24